Mycoplasma Female Infection Symptoms

Many people come in surprised after seeing the word "Mycoplasma" on the results sheet of a 12-type sexually transmitted infection test (vaginitis test). Yet even the same Mycoplasma has an entirely different meaning depending on the species. There are species closer to commensal bacteria that commonly live together inside the vagina, while there are also species classified as clear sexually transmitted pathogens. This article focuses, among them, on Mycoplasma genitalium. In the clinic, this organism is often a case where "leaving it alone even if present" does not apply, so it needs to be understood accurately on its own.

Mycoplasma genitalium, unlike Mycoplasma hominis or Ureaplasma that are commonly mentioned alongside it, is hard to view as simple normal flora inside the vagina. The U.S. Centers for Disease Control and Prevention (CDC) STI Treatment Guidelines (2021) and the British Association for Sexual Health and HIV (BASHH) guideline (2025) treat this organism as a sexually transmitted pathogen that can be a cause of non-gonococcal urethritis, cervicitis, and pelvic inflammatory disease.

To put it simply, if hominis is a "guest that may be there," genitalium is closer to "a pathogen that should be suspected as the cause when there are symptoms." So even if the two organisms are written equally on a single line in the results sheet, the weight accepted in clinical practice differs.

The characteristics of the organism itself are also distinctive. Mycoplasma is a very small bacterium without a rigid cell wall, so common antibiotics that target the cell wall (such as the penicillin family) do not work. This point leads directly to the treatment and resistance issues explained later.

Genitalium infection is not infrequently without symptoms. However, if symptoms occur, they can appear in the form of cervicitis and pelvic inflammatory disease. The patterns we often see in the clinic are summarized as follows.

• Vaginal discharge different from usual, changes in color or smell
• Vaginal bleeding after intercourse or irregular bleeding
• Stinging when urinating or frequent urge to urinate
• Dull pain in the lower abdomen or pelvis, pain during intercourse

A point to note is that such symptoms appear to overlap with other vaginitis or cystitis. So it is hard to pinpoint genitalium from symptoms alone, and testing is needed. If abnormal discharge or bleeding recurs, we recommend referring to the abnormal vaginal discharge or abnormal vaginal bleeding items and getting a medical visit.

The BASHH guideline (2025) and CDC guideline (2021) explain that genitalium can be associated with pelvic inflammatory disease in women, and that some studies report an association with tubal-factor infertility or adverse outcomes during pregnancy. However, this is a matter at the level of "possibility" and "association," and the fact that the organism was detected does not necessarily mean such outcomes will follow. There is no need to be vaguely afraid, but a balanced attitude that does not brush it off lightly when there are symptoms is necessary.

Genitalium is very difficult to grow by ordinary bacterial culture, so diagnosis is done by nucleic acid amplification testing (NAAT), that is, the PCR method. The 12-type sexually transmitted infection test performed in OB-GYN corresponds to this, and insurance coverage is often available when there are vaginitis symptoms. A single specimen collection checks several organisms together, and results usually take about a few days.

Another thing international guidelines recently emphasize is resistance gene testing. Both the CDC (2021) and BASHH (2025) recommend, when genitalium is detected, also checking for macrolide resistance markers if possible. This is to gauge in advance, at the detection stage, which antibiotic will work.

The parts patients often confuse regarding testing are organized in the table below.

A uniform screening test for asymptomatic people is not recommended in international guidelines. That is, rather than "let's test everyone because it's worrying," the principle is to test when there are symptoms or when clinically necessary. If you are curious about the test timing or insurance coverage, please use getting a test-related consultation by chat.

The most difficult topic with genitalium is precisely antibiotic resistance. As cases where the previously commonly used single-dose regimen is insufficient have increased, resistance to the macrolide family is reported to be rising in several regions. The CDC (2021) and BASHH (2025) explicitly state this spread of resistance as a worldwide concern.

The background to the increase in resistance is pointed out to be the practice of using antibiotics broadly, and briefly, for nonspecific genital infections. This is because using the medication halfheartedly gives the organism a chance to survive and acquire resistance. In the clinic, this context is often confirmed in people who say they repeatedly took "vaginitis medication" elsewhere before but did not get better well.

So the major direction of recent treatment is shifting toward the method of choosing the medication by looking at resistance information, so-called resistance-guided treatment. The judgment is that first grasping which medication the organism responds to and prescribing accordingly is more reasonable than blindly repeating a single medication.

The specific medications and doses vary depending on the patient's condition and resistance test results, so medical staff decide them. Explaining only the broad framework, it is as follows.

International guidelines present an approach of choosing medications in stages according to resistance test results. The CDC (2021) recommends a sequential method of first using the doxycycline family, then following with azithromycin if there is macrolide susceptibility, or with moxifloxacin if there is macrolide resistance. BASHH (2025) also follows a similar framework of varying the medication depending on susceptibility.

During treatment, a few lifestyle rules are important.

• Avoid sexual contact until a certain period has passed after treatment ends, and until symptoms have disappeared.
• Do not stop the prescribed antibiotics arbitrarily; take them to the end.
• The partner too may need evaluation and treatment, so it is good to discuss it together.

Men can also develop urethritis symptoms if infected with genitalium, and antibiotic treatment is needed in that case. To prevent reinfection, avoiding sexual contact until the partner's treatment is complete is recommended. There are also cases where a follow-up test to confirm cure is needed after treatment ends, so it is safer to wrap it up through a medical visit rather than self-judgment.

Mycoplasma genitalium, unlike common commensals, is treated as a sexually transmitted pathogen, and it is an organism that requires diagnosis and treatment when there are symptoms. However, there is no need to be excessively anxious over the single fact that the organism was detected. The key is accurate species identification, resistance testing when necessary, and treatment that reflects the resistance information.

The best prevention is to not leave symptoms unattended but to check them through regular lifecycle screening or women's disease treatment. If the results sheet is confusing or you are curious about the test/treatment direction, rather than worrying while searching alone, we recommend confirming it together in the clinic.

Written by: Lee Dong-hee Director · OB-GYN Specialist · View medical staff profile

First published May 2, 2024 · Last reviewed May 30, 2026

References: CDC STI Treatment Guidelines (2021), BASHH National Guideline for Mycoplasma genitalium (2025), European (IUSTI/WHO) Guideline on Mycoplasma genitalium (2021)

This article is intended to provide general health information and does not replace individual diagnosis or treatment. If you have symptoms, please consult through a medical visit.